These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 34033528)

  • 21. An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).
    Alagheband Bahrami A; Azargoonjahromi A; Sadraei S; Aarabi A; Payandeh Z; Rajabibazl M
    Cell Mol Biol Lett; 2022 May; 27(1):38. PubMed ID: 35562685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.
    Chavda VP; Yao Q; Vora LK; Apostolopoulos V; Patel CA; Bezbaruah R; Patel AB; Chen ZS
    Front Immunol; 2022; 13():961198. PubMed ID: 36263030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine Strategy During the SARS-CoV-2 Pandemic: What School Nurses Need to Know.
    Barnby E; Reynolds M; Gordon J
    NASN Sch Nurse; 2021 Nov; 36(6):316-322. PubMed ID: 34060925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A perspective on SARS-CoV-2 virus-like particles vaccines.
    Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
    Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 Vaccines: Where Are We Now?
    Flanagan KL; MacIntyre CR; McIntyre PB; Nelson MR
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3535-3543. PubMed ID: 34400116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.
    Kantarcioglu B; Iqbal O; Lewis J; Carter CA; Singh M; Lievano F; Ligocki M; Jeske W; Adiguzel C; Gerotziafas GT; Fareed J
    Clin Appl Thromb Hemost; 2022; 28():10760296211056648. PubMed ID: 35167393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 vaccines: a triumph of science and collaboration.
    Golob JL; Lugogo N; Lauring AS; Lok AS
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33822773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. People's Willingness to Vaccinate Against COVID-19 Despite Their Safety Concerns: Twitter Poll Analysis.
    Eibensteiner F; Ritschl V; Nawaz FA; Fazel SS; Tsagkaris C; Kulnik ST; Crutzen R; Klager E; Völkl-Kernstock S; Schaden E; Kletecka-Pulker M; Willschke H; Atanasov AG
    J Med Internet Res; 2021 Apr; 23(4):e28973. PubMed ID: 33872185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
    Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of mucosal immunity by a live-attenuated SARS-CoV-2 nasal vaccine.
    Yeung J; Wang T; Shi PY
    Curr Opin Virol; 2023 Oct; 62():101347. PubMed ID: 37604085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.
    Ghasemiyeh P; Mohammadi-Samani S; Firouzabadi N; Dehshahri A; Vazin A
    Int Immunopharmacol; 2021 Nov; 100():108162. PubMed ID: 34562844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes.
    AlJamaan F; Temsah MH; Alhasan K; Alenezi S; Alhaboob A; Alrabiaah A; Batais M; Alshahrani F; Assiri RA; Bafaqih H; Alaraj A; Al Qadrah B; Alhaidary A; Saad K; Saddik B; Halwani R; Rabaan AA; Al-Subaie S; Barry M; Al-Tawfiq JA
    J Infect Public Health; 2022 Jul; 15(7):773-780. PubMed ID: 35728424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and future nanoparticle vaccines for COVID-19.
    Vu MN; Kelly HG; Kent SJ; Wheatley AK
    EBioMedicine; 2021 Dec; 74():103699. PubMed ID: 34801965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.
    Sharma O; Sultan AA; Ding H; Triggle CR
    Front Immunol; 2020; 11():585354. PubMed ID: 33163000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promise and challenges in the development of COVID-19 vaccines.
    Chen W
    Hum Vaccin Immunother; 2020 Nov; 16(11):2604-2608. PubMed ID: 32703069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A survey of mechanisms underlying current and potential COVID-19 vaccines.
    Hebel C; Thomsen AR
    APMIS; 2023 Feb; 131(2):37-60. PubMed ID: 36394112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?
    Vandeputte J; Saville M; Cavaleri M; Friede M; Hacker A; Mueller SO; Rizzi R; Smith D; Thirstrup S; Wagner R; Baay M; Neels P
    Biologicals; 2021 Jun; 71():55-60. PubMed ID: 33966960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.